Tag: GlobeNewswire

– Agreement complements revenue from standard gene expression and DRP® services

– Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the United States

– Strategy expands commercial use of existing laboratory capabilities

– Stenoparib remains the Company’s top development priority

TARPON SPRINGS, Fla., October 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.

CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as blood, body fluids, and tissue. The agreement represents the first commercial validation of Allarity’s CLIA-certified laboratory services strategy following the Company’s receipt of CLIA certification in July 2026.

Under the agreement, Allarity will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States. Successful completion of the program could lead to ongoing commercial testing and CLIA-related service revenues.

“This agreement moves our newly established CLIA laboratory services strategy into commercial execution, building on our existing gene expression and DRP® services business,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “For shareholders, the opportunity is to generate additional value from capabilities we have already built while maintaining stenoparib as our top development priority.”

Allarity obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its Hørsholm laboratory, in part to enable the Company to perform biomarker testing internally in support of the continued clinical development of stenoparib and its DRP® companion diagnostic strategy.

The Company also identified the opportunity to offer its CLIA-certified laboratory capabilities to other biotechnology and pharmaceutical companies, particularly European drug developers seeking laboratory support for precision oncology programs intended for U.S. clinical development or commercialization. This first commercial agreement provides an initial foundation for pursuing that broader service opportunity.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the successful performance of services under the Company’s CLIA-certified laboratory services agreement; the potential for the agreement and the Company’s laboratory capabilities to generate recurring commercial revenue; future demand for the Company’s CLIA-certified services; the continued development of stenoparib and the Company’s DRP® companion diagnostic strategy; and the Company’s expectation that its existing working capital will be sufficient to fund operations into the summer of 2028. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks that the development or validation activities may not be successfully completed; that the customer’s program may not advance to commercial testing; that the agreement may not generate recurring revenues or lead to additional commercial agreements; changes in applicable regulatory requirements; and the possibility that the Company’s operating expenses, financing needs or other circumstances may differ from current expectations. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
      investorrelations@allarity.com
        
Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com

Attachment

• Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy

SCOTTSDALE, Ariz., Oct. 30, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq CWD), a diversified real estate and digital asset management platform, today announced that it will release its third quarter 2026 financial results after the close of the stock market on Thursday, November 12, 2026. Management invites all interested parties to its webcast/conference call the same day at 5:00 pm ET to discuss the results.

Investors and interested parties can access the live earnings call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) and ask to join the Caliber call or use conference ID 3070057.

To listen to the call online, investors can visit the investor relations page of Caliber’s website at https://ir.caliberco.com/. The webcast replay of the conference call will be available on Caliber’s website shortly after the call concludes.

Additional details:
The news release and presentation materials will also be available on the Investor Relations site under “Financial Results”.

About Caliber (CaliberCos Inc.)
Caliber (Nasdaq: CWD) is a real estate-focused alternative asset manager with over $2.6 billion in Managed Assets and a 17-year track record investing in middle-market hospitality and multifamily real estate. The Company pairs an institutional-quality asset management platform with a boutique, hands-on investment approach focused on value creation in underserved market segments. Investors can participate in Caliber through its publicly traded equity (Nasdaq: CWD), and through its private real estate investment funds for accredited investors and financial professionals. For more information, visit caliberco.com.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Company’s public offering filed with the SEC and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

CONTACTS:
Caliber Investor Relations:
Ilya Grozovsky
+1 480-214-1915
Ilya@CaliberCo.com

Transaction in Own Shares

29 October, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 29 October, 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
29/10/2026	821,526	£41.0800	£39.9400	£40.5003	LSE	GBP
29/10/2026	209,477	£41.0950	£39.9350	£40.5394	Chi-X (CXE)	GBP
29/10/2026	67,997	£41.0900	£39.9450	£40.5697	BATS (BXE)	GBP
29/10/2026	481,906	€49.3200	€47.9400	€48.5187	XAMS	EUR
29/10/2026	205,030	€49.3000	€47.9700	€48.5086	CBOE DXE	EUR
29/10/2026	26,758	€49.2000	€48.0300	€48.5050	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme announced on 29 October 2026.

In respect of this programme, BNP Paribas (with respect to the on-market limb) and Natixis (with respect to the off-market limb) will make trading decisions in relation to the securities independently of the Company for a period from 29 October 2026 up to and including 29 January 2027.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by BNP Paribas and Natixis on behalf of the Company as a part of the buy-back programme is detailed below.  

Enquiries

Media: International +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

LEI number of Shell plc: 21380068P1DRHMJ8KU70

Classification: Acquisition or disposal of the issuer’s own shares

Attachment

• SHELL_RNS_Report_PDF-20261029Cons

Grant protects deliverz.ai’s navigation technology, supporting Gix’s broader Physical AI strategy

TEL AVIV, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that its wholly owned subsidiary, deliverz.ai (“Deliverz”), has been granted a patent in South Korea (Application No. 10-2022-7013675) titled “NAVIGATION INDICATION OF A VEHICLE.” The formal grant follows the previously announced allowance of the application in August 2026.

The patent covers a method and system for providing navigation indications for a vehicle between two points, based in part on visual information from the surrounding environment. The invention describes a method and system for navigating a vehicle from a first location to a second location by using images captured from the vehicle’s surroundings to identify visual cues from a database of visual cues, and to generate accurate location information for the vehicle. The technology is intended to support autonomous vehicle and robot navigation.

The grant strengthens protection for navigation technology that supports Gix’s broader Physical AI strategy: an AI-powered management and orchestration layer coordinating robots, people and autonomous systems. The patent relates to navigation; the broader orchestration platform forms part of the Company’s business strategy.

The South Korean patent grant extends the international protection of this technology alongside patents already granted in Europe and Israel. The patent grant further expands the international protection of Deliverz’s technology and represents a positive development supporting the Company’s growth strategy.

Deliverz’s platform combines management software, autonomous mobile robots and human couriers to coordinate deliveries in real time. It allocates tasks by location, priority and availability from a central operations system, with the aim of improving reliability, throughput and cost efficiency in complex facilities such as hospitals.

“Our strategy is to build an intelligent management layer that coordinates robots, people and autonomous systems in real-world operations. Protecting the navigation technology used by our robots strengthens an important part of that foundation,” said Amir Nardimon, Chief Executive Officer of Gix. “The South Korean patent grant broadens our international IP protection as we continue to develop Deliverz’s commercial use in hospital logistics and pursue opportunities to apply our Physical AI platform in additional complex environments.”

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About deliverz.ai

deliverz.ai is defining the future of healthcare logistics automation with an end-to-end, AI-powered orchestration platform that unifies autonomous robots, human transport teams, and hospital workflows into a single intelligent system. Robot-agnostic and built to scale, deliverz.ai automates and optimizes logistics across any workflow and within any environment, increasing throughput, reducing costs, and improving both patient and staff experience. Delivered through a flexible Software as a Service (SaaS) and Robotics as a Service (RaaS) model, deliverz.ai provides the intelligent logistics backbone for hospitals, making operations smarter, faster, and patient-centered. For more information, visit https://www.deliverz.ai

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential contribution of the patent grant and patented technology to the Company’s Physical AI strategy, the potential applications and benefits of its technology, the continued development and commercialization of Deliverz’s technology, and the Company’s plans and objectives regarding the expansion of its Physical AI platform into additional operating environments. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites. IBM, IBM Quantum and the names of IBM quantum processors are trademarks of International Business Machines Corporation; IBM is not affiliated with, and has not endorsed, Gix, QXL or the results described in this press release.

Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com

MONTREAL, Oct. 30, 2026 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that its Board of Directors has approved a fourth-quarter 2026 dividend on the Company’s common shares outstanding. A quarterly dividend of ninety-one and a half cents (C$0.9150) per common share will be paid on December 30, 2026, to shareholders of record at the close of business on December 9, 2026.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:
Media	Investment Community
Ashley Michnowski	Jamie Lockwood
Senior Manager	Vice-President, Investor Relations
Media Relations	and Special Projects
(438) 596-4329	(514) 399-0052
media@cn.ca	investor.relations@cn.ca

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio’s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers:

• Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania
• Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, Virginia Mason Franciscan Health

A live question-and-answer session will follow the formal presentations. 

Interested parties should register for the event at the following link: HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor. A live webcast of the event will be accessible by visiting the Investor Relations section of the Braveheart Bio website at https://ir.braveheart.bio/. A link to the webcast replay will be available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced two upcoming presentations, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM, at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, IL. Following the presentations, copies of the presentation materials will be available in the Investors section of the Braveheart Bio website.

Oral Abstract Presentation

Title: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients
Presenter: Carlos del Rio, Ph.D., Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Abstract Oral Presentations
Session Time: 9:45 AM – 10:45 AM CT
Presentation Time: 10:15 AM – 10:25 AM CT
Location: Room S406A, McCormick Place

Late-Breaking Oral Abstract Presentation

Title: Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period
Presenter: Xueyi Wu, M.D., Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China​
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:15 PM – 2:25 PM CT
Location: Room S406A, McCormick Place

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com

VANCOUVER, British Columbia, Oct. 30, 2026 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce a series of strategic initiatives and leadership changes designed to position the Company for accelerated technical progress and discovery potential across its flagship Moonlite Project and broader portfolio in Saskatchewan’s prolific Athabasca Basin. These steps include the execution of a Master Services Agreement with Axiom Exploration Group Ltd. (“Axiom”), an amendment to its option agreement with Atha Energy Corp. (“Atha”) (TSX-V: SASK) that sets a path for the two companies to advance the optioned Moonlite Project ground as equal 50/50 joint venture partners and the appointment of experienced leaders to guide the Company into its next phase of growth.

These initiatives reflect the Board’s commitment to assembling a strong technical and leadership platform capable of executing a disciplined, well-supported exploration program in one of the world’s premier uranium districts. Stallion is well-positioned to build on the momentum generated by its 2026 drilling and geophysical work as it moves forward with an enhanced technical operational structure.

Doug Engdahl, P.Geo., President & CEO of Axiom Exploration Group, stated: “We are excited to formalize our relationship with Stallion Uranium and support the advancement of its high-quality Athabasca Basin portfolio. The combination of Stallion’s strategic land position, the ongoing partnership with Atha Energy, and the technical capabilities Axiom brings positions this collaboration for meaningful discovery potential. We look forward to delivering rigorous, results-oriented exploration that creates value for all stakeholders.”

Phase II will build directly on the geological, structural and radiometric information generated during the first phase of drilling and will continue testing priority areas along the Coyote corridor.

Master Services Agreement with Axiom Exploration Group
Stallion has entered into a Master Services Agreement with Axiom Exploration Group Ltd., a privately held, employee-owned technical firm specializing in geological, geophysical, environmental, remote sensing, engineering, and management consulting. Under the agreement, Axiom will provide technical, geological, geophysical, environmental, and related advisory, consulting, personnel, and equipment services in connection with Stallion’s exploration activities.

Key personnel made available under the agreement include Senior Technical Advisor Doug Engdahl, P.Geo. (President & CEO of Axiom), VP of Exploration Brent Jellicoe, P.Geo., Pri.Sci.Nat., and additional specialists in geology, GIS, and geophysics. Mr. Jellicoe, a highly accredited geologist with more than 34 years of global mineral exploration and consulting experience (including diamonds, rare earth elements, gold, lithium, and uranium), brings extensive expertise in NI 43-101 and JORC-compliant technical reporting, program management, and due diligence across Canada, Africa, Australia, and beyond.

Axiom’s involvement is expected to enhance technical rigor, operational efficiency, and discovery-oriented targeting as Stallion advances its Athabasca programs.

The Company remains focused on the ongoing 2026 program at Coyote, where early drilling has delivered encouraging results that have already informed program expansion. Systematic testing of priority targets continues, guided by integrated geophysics, structural interpretation, and the drilling data generated to date.

Building on the extensive exploration work completed to date, Stallion Uranium is advancing a systematic, data-driven exploration strategy designed to refine existing targets and unlock additional discovery opportunities across its highly prospective uranium portfolio. Incorporating results from the Company’s recent drilling programs, Stallion will recalibrate and enhance its geophysical models to improve the interpretation of subsurface structures and potential uranium mineralization controls.

This work will be complemented by a series of targeted geophysical surveys, geochemical data collection, and integrated geological and geophysical modelling to further refine the Company’s exploration framework. These initiatives will support and augment the ongoing drill campaign, strengthen the technical understanding of priority exploration corridors, and generate a pipeline of additional high-priority, drill-ready targets, positioning Stallion to systematically advance its exploration portfolio and maximize its potential for new uranium discoveries.

Michelle Roth, Interim CEO of Stallion, commented: “Axiom brings an accomplished team of geologists and geophysicists to Stallion, and with Atha supporting them in an advisory role, we have the technical depth to advance our exploration efficiently and make every dollar count for shareholders. I’m excited to help guide the Company through this transition period and look forward to working with Doug, Brent and the Axiom team as they move our programs forward.”

Continued Partnership with Atha Energy and Technical Advisory Role
Stallion and Atha Energy will continue to work collaboratively on the option agreement ground within the southwestern Athabasca Basin, including the Moonlite Project and its high-priority Coyote Target. Atha maintains one of the largest cumulative exploration packages in the Athabasca Basin, and will serve as technical advisor to Axiom. This arrangement leverages Atha’s deep uranium expertise and technical bench strength to support data integration, targeting, and program execution while preserving the productive partnership between Stallion and Atha as they move toward forming a joint venture.

Leadership Transitions
The Board of Directors announces the following management changes:

• Matthew Schwab will step down as Chief Executive Officer. The Board thanks Mr. Schwab for his contributions to the Company, including his role in advancing the technical understanding of the Moonlite Project and the Coyote Target.
• Michelle Roth has been appointed Interim Chief Executive Officer, effective immediately. Ms. Roth is an entrepreneur and business leader who founded Roth Investor Relations in 1987. Over 35 years she advised mining clients ranging from producers to developers and explorers with assets across North America, Australia, Africa, Europe, and South America, covering commodities including gold, silver, platinum, copper, diamond, nickel, and ferrochrome. She currently serves as a Non-Executive Director and Audit Chair of Velocity Minerals Ltd. (TSX-V: VLC) and on its Compensation, Nominating, and Governance Committees, and as a Non-Executive Director of Lac Gold Limited (ASX: LAC, previously Ardiden Limited), where she previously served as Chairperson prior to the merger. She has also served as Chairperson of Maple Gold Mines Ltd. (TSX-V: MGM) and Chair of its Audit and Nominating and Governance Committees. Ms. Roth holds an MBA in Finance from Fordham University and a BA (Hons) in Political Science from the University at Albany. The Board is confident that her extensive capital-markets, governance, and mining-industry experience will provide strong leadership as Stallion executes its exploration strategy.
• Darren Slugoski has stepped down from his position as Vice President of Exploration of the Company, effective immediately. The Board thanks Mr. Slugoski for his contributions to the Company’s exploration programs in the Athabasca Basin.
• Paulo Santos will transition from his role as Chief Financial Officer to focus full-time on his responsibilities as CFO of StrikePoint Gold Inc. The Board thanks Mr. Santos for his dedicated service and contributions to Stallion’s financial reporting, treasury, and compliance functions.
• The Company is pleased to welcome Xavier Wenzel, CPA, CA, as Chief Financial Officer. Mr. Wenzel brings more than 25 years of finance and public accounting experience, with extensive senior roles in the mining and resource sector, including current and former CFO positions with companies such as Chakana Copper Corp., Pure Energy Minerals Ltd., Empress Royalty Corp., and NuLegacy Gold Corporation. As a principal at Fehr & Associates and a member of the Chartered Professional Accountants of British Columbia, he has deep expertise in financial reporting, regulatory compliance, and corporate finance under IFRS and US GAAP.

Paulo Santos, outgoing CFO, commented, “I am pleased to recommend Xavier Wenzel for the role of CFO. Having worked closely with him in the past within the mining finance community, I am confident he will provide excellent continuity and stewardship as Stallion advances its programs.”

Amended Option Agreement with Atha Energy
Stallion and Atha have entered into an amending agreement dated effective October 29, 2026 (the “Amendment”) to their option agreement dated effective July 18, 2023 (the “Option Agreement”), under which Stallion holds the option to earn a 70% interest in certain Saskatchewan mining claims. Under the Amendment, Stallion’s option has been reduced to a 50% retained interest. In addition, Stallion may receive a $2,500,000 payment from Atha if a material discovery is been made on the claims that are the subject of the Option Agreement. The conditions Stallion must meet to exercise its option, including the required exploration expenditures, are unchanged.

Grant of Stock Options
In connection with her appointment, Ms. Roth has been granted incentive stock options to purchase an aggregate of 200,000 common shares of the Company (each an “Option”) pursuant to the Company’s stock option plan, at an exercise price of $0.13 per share. The Options have a term of eighteen (18) months from the date of grant and vest immediately. The grant of Options remains subject to approval of the TSX Venture Exchange.

About Stallion Uranium
Stallion Uranium is a uranium exploration company focused on its significant land package in the Athabasca Basin, Saskatchewan, including the Moonlite Project (encompassing both 100%-owned claims and claims optioned from Atha Energy). The Company is advancing multiple high-priority targets, including the Coyote corridor, with the goal of discovering high-grade uranium mineralization to support the future of clean nuclear energy.

About Axiom Exploration Group Ltd.
Axiom Exploration Group Ltd. is a privately held, employee-owned technical firm specializing in geological, environmental, geophysical, remote sensing, engineering, and management consulting services for the mineral exploration sector.

About Atha Energy Corp.
Atha Energy Corp. is a uranium exploration company with a large land position in the Athabasca Basin and advanced projects elsewhere in Canada.

For more information, please contact:

Michelle Roth
Interim CEO
Stallion Uranium Corp.
Email: info@stallionuranium.com
Website: www.stallionuranium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”), and all statements in this news release other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to: the execution and expected benefits of the Master Services Agreement with Axiom Exploration Group Ltd. and the amended option agreement with Atha Energy Corp., including the potential path to an equal 50/50 joint venture on the Moonlite Project; Atha’s right (but not obligation) to make a cash payment of $2,500,000 to Stallion upon the occurrence of a material discovery, and the anticipated use of any such proceeds to fund exploration and for general working capital; the effect of the Acquisition Payment on the parties’ respective interests in the Property, including Stallion’s earn-in reducing to 50% and Atha’s retained interest increasing to 50%; the governance and operational structure of the contemplated joint venture, the expected continuation and expansion of the 2026 drill program at the Coyote Target; and the Amendment’s anticipated acceptance by the TSX Venture Exchange; all of which are based on the beliefs, estimates, and opinions of Stallion’s management on the date such statements are made and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements, including, without limitation: risks associated with the formation and operation of the contemplated joint venture, including disputes between joint venture partners; uncertainty that the TSX Venture Exchange will accept the Amendment on the terms described or at all; exploration risks, including the risk that drilling, geophysical, or geochemical programs do not identify economic uranium mineralization; general risks associated with mineral exploration, including unpredictable results, increased costs, and regulatory requirements; risks related to changes in uranium commodity prices; risks related to the ability to obtain required financing for exploration activities; and general economic, market, and business conditions; and there can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements, and accordingly readers should not place undue reliance on forward-looking statements, and Stallion does not undertake any obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws, and the forward-looking statements contained in this news release are expressly qualified by this cautionary note.

• Delivered diluted earnings per share (EPS) of C$2.00, an increase of 9% and adjusted diluted EPS of C$2.16, an increase of 18%, or 17% at constant currency ⁽¹⁾
• Generated free cash flow of C$2,918 million, an increase of 25% for the first nine months of 2026 (consisting of net cash provided by operating activities of C$4,780 million and net cash used in investing activities of C$1,862 million) ⁽¹⁾
• Realized record third quarter fuel efficiency performance and on track for annual record
• Repurchased approximately 3.9 million shares for C$676 million

MONTREAL, Oct. 30, 2026 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) today reported its financial and operating results for the third quarter ended September 30, 2026.

“I am very proud of CN’s dedicated railroaders for delivering another strong quarter. Their relentless focus on safely executing the plan across our unique network continues to strengthen service, enhance productivity, and support our customers’ success. Together with our disciplined financial management, these rigorous efforts position CN to deliver profitable growth, continue to create long-term value for our shareholders, and capitalize on the opportunities ahead.”

– Tracy Robinson, President and Chief Executive Officer, CN

Third-Quarter 2026 Results Highlights
CN’s commercial momentum and service performance were supported by a 4% increase in gross ton miles (GTMs) to 116,264 (millions) and a 4% increase in RTMs to 59,383 (millions). The Company delivered diluted EPS of C$2.00, an increase of 9%, and adjusted diluted EPS of C$2.16, an increase of 18%, or C$2.14 on an adjusted basis at constant currency, an increase of 17%. ⁽¹⁾

The quarter’s operating performance reflects CN’s commitment to strong service execution, enabling its ability to meet customer demand in key markets including grain and energy, while continuing to advance operational improvements through Fast Track.

Quarterly Financial Results Highlights
Third-quarter 2026 compared to third-quarter 2025

• Revenues of C$4,771 million, an increase of C$606 million, or 15%.
• Operating income of C$1,730 million, an increase of C$124 million, or 8%, and adjusted operating income of C$1,862 million, an increase of C$256 million, or 16%. ⁽¹⁾
• Operating ratio, defined as operating expenses as a percentage of revenues, of 63.7%, an increase of 230 basis points, and adjusted operating ratio of 61.0%, an improvement of 40 basis points. ⁽¹⁾
• Net income of C$1,209 million, an increase of C$70 million, or 6%, and adjusted net income of C$1,307 million, an increase of C$168 million, or 15%. ⁽¹⁾
• Diluted EPS of C$2.00, an increase of 9% and adjusted diluted EPS of C$2.16, an increase of 18%, or C$2.14 on an adjusted basis at constant currency, an increase of 17%. ⁽¹⁾
• Free cash flow for the first nine months of 2026 was C$2,918 million, an increase of C$577 million, or 25%. ⁽¹⁾
• Adjusted EBITDA reported for the twelve months ended September 30, 2026 of C$9,080 million, an increase of 5%. ⁽¹⁾
• Adjusted debt-to-adjusted EBITDA of 2.61 times as at and for the twelve months ended September 30, 2026. ⁽¹⁾
• Repurchased approximately 3.9 million shares in the third quarter of 2026 for C$676 million.

Quarterly Operating Performance Highlights *
Third-quarter 2026 compared to third-quarter 2025

• GTMs increased 4% to 116,264 (millions).
• RTMs increased 4% to 59,383 (millions).
• Through dwell increased by 1% to 7.1 (entire railroad, hours).
• Car velocity decreased by 2% to 207 (car miles per day).
• Through network train speed decreased by 2% to 19.1 (mph).
• Fuel efficiency of 0.814 (US gallons of locomotive fuel consumed per 1,000 GTMs), was 2% more efficient.
• Train length remained flat at 8,083 (feet).
• GTMs per average number of employees increased 7% to 4,888 (thousands).
• Operating expenses per GTM increased 14% to 2.62 (cents).

_{* Statistical operating data and key operating measures are unaudited and based on estimated data available at such time and are subject to change as more complete information becomes available.}

Dividends
CN’s Board of Directors has approved a fourth-quarter 2026 dividend on the Company’s common shares outstanding. A quarterly dividend of ninety-one and a half cents (C$0.9150) per common share will be paid on December 30, 2026, to shareholders of record at the close of business on December 9, 2026.

2026 financial guidance ⁽¹⁾⁽²⁾
The Company continues to assume to deliver low single-digit RTM growth in 2026. The Company continues to expect adjusted diluted EPS growth in the mid-to-high single-digit range and is currently tracking more towards the upper end of this range.

In 2026, CN is still on track to invest approximately C$2.8 billion in its capital program, net of amounts reimbursed by customers. The Company also expects to continue improving its free cash flow conversion throughout 2026.

CONFERENCE CALL DETAILS
CN’s senior officers will review the results and the railway’s outlook in a conference call starting at 8:30 a.m. Eastern Time on October 30, 2026. Tracy Robinson, CN President and Chief Executive Officer, will lead the call. Parties wishing to participate via telephone may dial 1-800-715-9871 (Canada/U.S.), or 1-647-932-3411 (International), using 5186426 as the passcode. Participants are advised to dial in 10 minutes prior to the call.

_{(1) Non-GAAP Measures
CN reports its financial results in accordance with United States generally accepted accounting principles (GAAP). CN may also use non-GAAP measures in this news release that do not have any standardized meaning prescribed by GAAP. These non-GAAP measures may not be comparable to similar measures presented by other companies. For further details of these non-GAAP measures, including a reconciliation to the most directly comparable GAAP financial measures, refer to the attached supplementary schedule, Non-GAAP Measures.}

_{CN’s outlook, guidance or targets (2) exclude certain adjustments, which are expected to be comparable to adjustments made in prior years. However, management cannot individually quantify on a forward-looking basis the impact of these adjustments, which could be significant, are difficult to predict and may be highly variable. As a result, CN does not provide a corresponding GAAP measure for, or reconciliation to, its outlook, guidance or targets.}

_{(2) Forward-Looking Statements
Certain statements included in this news release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and under Canadian securities laws, including statements based on management’s assessment and assumptions and publicly available information with respect to CN. By their nature, forward-looking statements involve risks, uncertainties and assumptions. CN cautions that its assumptions may not materialize and that current economic conditions render such assumptions, although reasonable at the time they were made, subject to greater uncertainty. Forward-looking statements may be identified by the use of terminology such as “believes,” “expects,” “anticipates,” “assumes,” “outlook,” “plans,” “targets,” “goals,” or other similar words.}

_{2026 key assumptions
CN has made a number of economic and market assumptions in preparing its 2026 outlook. The 2025/2026 grain crops in Canada and the U.S. were above their respective five-year averages. The Company now assumes that the 2026/2027 grain crops in Canada and the U.S. will be above their respective five-year averages (compared to its January 30, 2026 assumption that the 2026/2027 grain crops in Canada and the U.S. will be in line with their respective five-year averages). CN continues to assume low single-digit RTM growth. CN continues to assume that for the balance of 2026, the value of the Canadian dollar in U.S. currency will be $0.71 and the average price of crude oil (West Texas Intermediate) will be in the range of US$80 – US$110 per barrel. The Company notes there is a heightened demand risk as a result of volatile macroeconomic conditions, geopolitical conflicts and global trade tensions.}

_{Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors which may cause actual results, performance or achievements of CN to be materially different from the outlook or any future results, performance or achievements implied by such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements. Important risk factors that could affect the forward-looking statements in this news release include, but are not limited to, general economic and business conditions, including factors impacting global supply chains such as pandemics and geopolitical conflicts or tensions; trade restrictions, trade barriers, or the imposition of tariffs or other changes to international trade arrangements; industry competition; inflation, currency and interest rate fluctuations; changes in fuel prices; legislative and/or regulatory developments; compliance with environmental laws and regulations; actions by regulators and other regulatory claims or proceedings; increases in maintenance and operating costs; security threats; reliance on technology, including the use of artificial intelligence, and related cybersecurity risk; transportation of hazardous materials; various events which could disrupt operations, including illegal blockades of rail networks, and natural events such as severe weather, droughts, fires, floods and earthquakes; climate change; labor negotiations and disruptions; environmental claims; uncertainties of investigations, proceedings and other types of claims and litigation; risks and liabilities arising from derailments; timing and completion of capital programs; the availability of and cost competitiveness of renewable fuels and the development of new locomotive propulsion technology; reputational risks; supplier concentration; pension funding requirements and volatility; and other risks detailed from time to time in reports filed by CN with securities regulators in Canada and the United States. Reference should also be made to Management’s Discussion and Analysis (MD&A) in CN’s annual and interim reports, Annual Information Form and Form 40-F, filed with Canadian and U.S. securities regulators and available on CN’s website, for a description of major risk factors relating to CN.}

_{The achievement of CN’s climate goals is subject to several risks and uncertainties, including those disclosed in the MD&A in CN’s annual and interim reports. There can be no certainty that the Company will achieve any or all of these goals within the stated timeframe, or that achieving any of these goals will meet all of the expectations of its stakeholders or applicable legal requirements.}

_{Forward-looking statements reflect information as of the date on which they are made. CN assumes no obligation to update or revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities laws. In the event CN does update any forward-looking statement, no inference should be made that CN will make additional updates with respect to that statement, related matters, or any other forward-looking statement. Information contained on, or accessible through, our website is not incorporated by reference into this news release.}

This earnings news release, as well as additional information, including the Financial Statements, Notes thereto and MD&A, is contained in CN’s Quarterly Review available on the Company’s website at www.cn.ca/financial-results and on SEDAR+ at www.sedarplus.ca as well as on the U.S. Securities and Exchange Commission’s website at www.sec.gov through EDGAR.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:
Media	Investment Community
Ashley Michnowski	Jamie Lockwood
Senior Manager	Vice-President, Investor Relations
Media Relations	and Special Projects
(438) 596-4329	(514) 399-0052
media@cn.ca	investor.relations@cn.ca

SELECTED RAILROAD STATISTICS – UNAUDITED

	Three months ended September 30			Nine months ended September 30
	2026	2025		2026	2025
Financial measures
Key financial performance indicators (1)
Total revenues ($ millions)	4,771	4,165		13,903	12,840
Freight revenues ($ millions)	4,574	3,991		13,400	12,369
Operating income ($ millions)	1,730	1,606		5,060	4,854
Adjusted operating income ($ millions) (2)(3)	1,862	1,606		5,226	4,854
Net income ($ millions)	1,209	1,139		3,604	3,472
Adjusted net income ($ millions) (2)(3)	1,307	1,139		3,670	3,472
Diluted earnings per share ($)	2.00	1.83		5.93	5.54
Adjusted diluted earnings per share ($) (2)(3)	2.16	1.83		6.03	5.54
Net cash provided by operating activities ($ millions)	1,904	1,913		4,780	4,822
Net cash used in investing activities ($ millions)	828	1,120		1,862	2,481
Free cash flow ($ millions) (2)(4)	1,076	793		2,918	2,341
Gross property additions ($ millions)	805	1,105		1,939	2,429
Share repurchases ($ millions)	676	1,041		1,999	1,448
Dividends per share ($)	0.9150	0.8875		2.7450	2.6625
Financial ratio
Operating ratio (%) (5)	63.7	61.4		63.6	62.2
Adjusted operating ratio (%) (2)(3)	61.0	61.4		62.4	62.2
Operational measures (6)
Statistical operating data
Gross ton miles (GTMs) (millions)	116,264	111,901		355,735	344,079
Revenue ton miles (RTMs) (millions)	59,383	57,188		183,467	176,452
Carloads (thousands)	1,364	1,368		4,109	4,095
Route miles (includes Canada and the U.S., end of period)	18,900	18,900		18,900	18,900
Employees (end of period)	23,822	24,237		23,822	24,237
Employees (average for the period)	23,784	24,408		23,685	24,679
Key operating measures
Freight revenue per RTM (cents)	7.70	6.98		7.30	7.01
Freight revenue per carload ($)	3,353	2,917		3,261	3,021
GTMs per average number of employees (thousands)	4,888	4,585		15,019	13,942
Operating expenses per GTM (cents)	2.62	2.29		2.49	2.32
Labor and fringe benefits expense per GTM (cents)	0.75	0.73		0.75	0.75
Diesel fuel consumed (US gallons in millions)	94.6	93.2		301.4	300.0
Average fuel price ($ per US gallon)	6.09	3.82		5.24	3.93
Fuel efficiency (US gallons of locomotive fuel consumed per 1,000 GTMs)	0.814	0.833		0.847	0.872
Train weight (tons)	9,370	9,225		9,357	9,141
Train length (feet)	8,083	8,049		8,013	7,923
Car velocity (car miles per day)	207	211		206	204
Through dwell (entire railroad, hours)	7.1	7.0		7.2	7.2
Through network train speed (miles per hour)	19.1	19.5		18.9	18.7
Locomotive utilization (trailing GTMs per total horsepower)	200	191		200	188
Safety indicators (7)
Injury frequency rate (per 200,000 person hours)	0.80	1.18		0.97	1.04
Accident rate (per million train miles)	1.51	1.92		2.09	1.84

(1)	Amounts expressed in Canadian dollars and prepared in accordance with United States generally accepted accounting principles (GAAP), unless otherwise noted.
(2)	These non-GAAP measures do not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies.
(3)	See the supplementary schedule entitled Non-GAAP Measures – Adjusted performance measures for an explanation of these non-GAAP measures.
(4)	See the supplementary schedule entitled Non-GAAP Measures – Free cash flow for an explanation of this non-GAAP measure.
(5)	Operating ratio is defined as operating expenses as a percentage of revenues.
(6)	Statistical operating data, key operating measures and safety indicators are unaudited and based on estimated data available at such time and are subject to change as more complete information becomes available. Definitions of gross ton miles, revenue ton miles, freight revenue per RTM, fuel efficiency, train weight, train length, car velocity, through dwell and through network train speed are included within the Company’s Management’s Discussion and Analysis. Definitions of all other indicators are provided on CN’s website, www.cn.ca/glossary.
(7)	Based on Federal Railroad Administration (FRA) reporting criteria.

SUPPLEMENTARY INFORMATION – UNAUDITED

	Three months ended September 30							Nine months ended September 30
	2026	2025	% Change Fav (Unfav)		% Change at constant currency (1) Fav (Unfav)			2026	2025	% Change Fav (Unfav)		% Change at constant currency (1) Fav (Unfav)
Revenues ($ millions) (2)
Petroleum and chemicals	1,000	854	17	%	16	%		2,869	2,577	11	%	12	%
Metals and minerals	561	477	18	%	16	%		1,557	1,496	4	%	5	%
Forest products	495	451	10	%	8	%		1,424	1,406	1	%	2	%
Coal	246	237	4	%	3	%		708	725	(2	%)	(2	%)
Grain and fertilizers	923	775	19	%	18	%		2,952	2,560	15	%	16	%
Intermodal	1,065	980	9	%	8	%		3,114	2,928	6	%	7	%
Automotive	284	217	31	%	29	%		776	677	15	%	15	%
Total freight revenues	4,574	3,991	15	%	14	%		13,400	12,369	8	%	9	%
Other revenues	197	174	13	%	12	%		503	471	7	%	7	%
Total revenues	4,771	4,165	15	%	14	%		13,903	12,840	8	%	9	%
Revenue ton miles (RTMs) (millions) (3)
Petroleum and chemicals	12,260	11,662	5	%	5	%		36,818	34,238	8	%	8	%
Metals and minerals	7,311	6,871	6	%	6	%		20,397	20,697	(1	%)	(1	%)
Forest products	4,978	5,159	(4	%)	(4	%)		15,106	15,659	(4	%)	(4	%)
Coal	4,888	5,131	(5	%)	(5	%)		14,793	15,635	(5	%)	(5	%)
Grain and fertilizers	16,333	14,562	12	%	12	%		54,227	48,325	12	%	12	%
Intermodal	12,680	13,027	(3	%)	(3	%)		39,473	39,469	—	%	—	%
Automotive	933	776	20	%	20	%		2,653	2,429	9	%	9	%
Total RTMs	59,383	57,188	4	%	4	%		183,467	176,452	4	%	4	%
Freight revenue / RTM (cents) (2)(3)
Petroleum and chemicals	8.16	7.32	11	%	10	%		7.79	7.53	3	%	4	%
Metals and minerals	7.67	6.94	11	%	9	%		7.63	7.23	6	%	6	%
Forest products	9.94	8.74	14	%	12	%		9.43	8.98	5	%	6	%
Coal	5.03	4.62	9	%	8	%		4.79	4.64	3	%	3	%
Grain and fertilizers	5.65	5.32	6	%	5	%		5.44	5.30	3	%	3	%
Intermodal	8.40	7.52	12	%	11	%		7.89	7.42	6	%	7	%
Automotive	30.44	27.96	9	%	8	%		29.25	27.87	5	%	5	%
Total freight revenue / RTM	7.70	6.98	10	%	9	%		7.30	7.01	4	%	5	%
Carloads (thousands) (3)
Petroleum and chemicals	171	162	6	%	6	%		511	479	7	%	7	%
Metals and minerals	236	225	5	%	5	%		684	677	1	%	1	%
Forest products	69	68	1	%	1	%		206	212	(3	%)	(3	%)
Coal	109	122	(11	%)	(11	%)		327	355	(8	%)	(8	%)
Grain and fertilizers	181	163	11	%	11	%		570	518	10	%	10	%
Intermodal	542	576	(6	%)	(6	%)		1,649	1,695	(3	%)	(3	%)
Automotive	56	52	8	%	8	%		162	159	2	%	2	%
Total carloads	1,364	1,368	—	%	—	%		4,109	4,095	—	%	—	%
Freight revenue / carload ($) (2)(3)
Petroleum and chemicals	5,848	5,272	11	%	10	%		5,614	5,380	4	%	5	%
Metals and minerals	2,377	2,120	12	%	11	%		2,276	2,210	3	%	4	%
Forest products	7,174	6,632	8	%	7	%		6,913	6,632	4	%	5	%
Coal	2,257	1,943	16	%	15	%		2,165	2,042	6	%	6	%
Grain and fertilizers	5,099	4,755	7	%	6	%		5,179	4,942	5	%	5	%
Intermodal	1,965	1,701	16	%	15	%		1,888	1,727	9	%	10	%
Automotive	5,071	4,173	22	%	20	%		4,790	4,258	12	%	13	%
Total freight revenue / carload	3,353	2,917	15	%	14	%		3,261	3,021	8	%	8	%

(1)	This non-GAAP measure does not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies. See the supplementary schedule entitled Non-GAAP Measures – Constant currency for an explanation of this non-GAAP measure.
(2)	Amounts expressed in Canadian dollars.
(3)	Statistical operating data and related key operating measures are unaudited and based on estimated data available at such time and are subject to change as more complete information becomes available.

NON-GAAP MEASURES – UNAUDITED

In this supplementary schedule, the “Company” or “CN” refers to Canadian National Railway Company, together with its wholly-owned subsidiaries. Financial information included in this schedule is expressed in Canadian dollars, unless otherwise noted.

CN reports its financial results in accordance with United States generally accepted accounting principles (GAAP). The Company also uses non-GAAP measures that do not have any standardized meaning prescribed by GAAP, including adjusted performance measures, free cash flow, constant currency and adjusted debt-to-adjusted EBITDA multiple. These non-GAAP measures may not be comparable to similar measures presented by other companies. From management’s perspective, these non-GAAP measures are useful measures of performance and provide investors with supplementary information to assess the Company’s results of operations and liquidity. These non-GAAP measures should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP.

Adjusted performance measures

Adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted operating expenses and adjusted operating ratio are non-GAAP measures that are used to set performance goals and to measure CN’s performance and may include the following adjustments:

1. operating expense adjustments: workforce reduction program, advisory costs related to rail consolidation matters, depreciation expense on the deployment of a replacement system, advisory fees related to shareholder matters, asset impairments and held-for-sale recoveries, business acquisition-related costs;
2. non-operating expense adjustments: business acquisition-related financing fees, merger termination income, gains and losses on disposal of property; and
3. the effect of changes in tax laws including rate enactments and changes in tax positions affecting prior years.

These non-GAAP measures do not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies.

For the three and nine months ended September 30, 2026, the Company’s adjusted net income was $1,307 million, or $2.16 per diluted share, and $3,670 million, or $6.03 per diluted share, respectively. The adjusted figures for the three and nine months ended September 30, 2026 exclude:

• asset impairments related to CN’s decision to discontinue the development of certain components of its dispatching and back office information technology projects before completion of $118 million, or $87 million after tax ($0.14 per diluted share) recorded in the third quarter in Asset impairments within the Consolidated Statements of Income, representing the full carrying amount of the affected software components, which had no alternative use and were no longer expected to provide future economic benefits;
• advisory costs related to the analysis and advocacy for the U.S. Surface Transportation Board (STB) review of the impacts to fair competition pertaining to the potential merger between Union Pacific and Norfolk Southern, including participation in ongoing merger-related regulatory proceedings, discovery activities and efforts to secure competitive access conditions, of $14 million, or $11 million after-tax ($0.02 per diluted share) and $48 million, or $36 million after tax ($0.05 per diluted share), respectively, recorded in Purchased services and material within the Consolidated Statements of Income; and
• the sale of a portion of the Newmarket subdivision located in Washago and Sundridge, Ontario, Canada, together with rail fixtures, for cash proceeds of $84 million, which resulted in a gain of $66 million, or $57 million after-tax ($0.09 per diluted share) recorded in the first quarter in Other income within the Consolidated Statements of Income.

For the three and nine months ended September 30, 2025, the Company’s net income was $1,139 million, or $1.83 per diluted share, and $3,472 million, or $5.54 per diluted share, respectively. There were no adjustments in the third quarter and the first nine months of 2025.

Adjusted net income is defined as Net income in accordance with GAAP adjusted for certain significant items. Management believes that adjusted net income provides additional insight to management and investors into the Company’s operations and underlying business trends as well as facilitates period-to-period comparisons, as it excludes certain significant items that are not reflective of CN’s underlying business operations and could distort the analysis of trends in business performance. Adjusted diluted earnings per share is defined as adjusted net income divided by the weighted-average diluted shares outstanding. This measure helps management and investors evaluate the Company’s profitability on a per-share basis, facilitating the assessment of period-over-period performance by removing the impact of significant, non-recurring items.

The following table provides a reconciliation of Net income and Earnings per share in accordance with GAAP, as reported for the three and nine months ended September 30, 2026 and 2025, to the non-GAAP adjusted performance measures presented herein:

	Three months ended September 30					Nine months ended September 30
In millions, except per share data		2026			2025		2026			2025
Net income	$	1,209		$	1,139	$	3,604		$	3,472
Adjustments:
Operating expense adjustments:
Asset impairments		118			—		118			—
Advisory costs related to rail consolidation matters		14			—		48			—
Non-operating expense adjustment:
Gain on disposal of property		—			—		(66	)		—
Tax adjustment:
Tax effect of adjustments (1)		(34	)		—		(34	)		—
Total adjustments	$	98		$	—	$	66		$	—
Adjusted net income	$	1,307		$	1,139	$	3,670		$	3,472
Diluted earnings per share	$	2.00		$	1.83	$	5.93		$	5.54
Impact of adjustments, per share		0.16			—		0.10			—
Adjusted diluted earnings per share	$	2.16		$	1.83	$	6.03		$	5.54

(1)	The tax impact of adjustments is based on the nature of the item for tax purposes and related tax rates in the applicable jurisdiction.

Adjusted operating income is defined as Operating income in accordance with GAAP adjusted for certain significant operating expense items that are not reflective of CN’s underlying business operations. This measure helps management and investors assess the Company’s core operating results by excluding items that may distort the analysis of ongoing business performance. Adjusted operating expenses is defined as Operating expenses in accordance with GAAP adjusted for certain significant operating expense items that are not reflective of CN’s underlying business operations. This measure provides management and investors with a view of ongoing costs which exclude unusual or non-recurring items, enabling more accurate assessment of cost management and resource allocation across reporting periods. Adjusted operating ratio is defined as adjusted operating expenses as a percentage of revenues. For management and investors, the adjusted operating ratio serves as a key performance indicator of cost management and overall operational effectiveness, as it demonstrates how effectively management controls costs relative to total revenue by excluding unusual or non-recurring items.

The following table provides a reconciliation of Operating income, Operating expenses and operating ratio, as reported for the three and nine months ended September 30, 2026 and 2025, to the non-GAAP adjusted performance measures presented herein:

	Three months ended September 30						Nine months ended September 30
In millions, except percentages		2026			2025			2026			2025
Operating income	$	1,730		$	1,606		$	5,060		$	4,854
Adjustments:
Asset impairments		118			—			118			—
Advisory costs related to rail consolidation matters		14			—			48			—
Total adjustments	$	132		$	—		$	166		$	—
Adjusted operating income	$	1,862		$	1,606		$	5,226		$	4,854
Operating expenses	$	3,041		$	2,559		$	8,843		$	7,986
Total adjustments		(132	)		—			(166	)		—
Adjusted operating expenses	$	2,909		$	2,559		$	8,677		$	7,986
Operating ratio		63.7	%		61.4	%		63.6	%		62.2	%
Impact of adjustments		(2.7	)%		—	%		(1.2	)%		—	%
Adjusted operating ratio		61.0	%		61.4	%		62.4	%		62.2	%

Free cash flow

Free cash flow is a useful measure of liquidity as it demonstrates the Company’s ability to generate cash for debt obligations and for discretionary uses such as payment of dividends, share repurchases, and strategic opportunities. The Company defines its free cash flow measure as the difference between net cash provided by operating activities and net cash used in investing activities, adjusted for the impact of (i) business acquisitions and combinations; and (ii) merger transaction-related payments, cash receipts and cash income taxes, which are items that are not indicative of operating trends. Free cash flow does not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies.

The following table provides a reconciliation of net cash provided by operating activities in accordance with GAAP, as reported for the three and nine months ended September 30, 2026 and 2025, to the non-GAAP free cash flow presented herein:

	Three months ended September 30						Nine months ended September 30
In millions		2026			2025			2026			2025
Net cash provided by operating activities	$	1,904		$	1,913		$	4,780		$	4,822
Net cash used in investing activities		(828	)		(1,120	)		(1,862	)		(2,481	)
Free cash flow	$	1,076		$	793		$	2,918		$	2,341

Constant currency

Financial results at constant currency allow results to be viewed without the impact of fluctuations in foreign currency exchange rates, thereby facilitating period-to-period comparisons in the analysis of trends in business performance. Measures at constant currency are considered non-GAAP measures and do not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies. Financial results at constant currency are obtained by translating the current period results denominated in US dollars at the weighted average foreign exchange rates used to translate transactions denominated in US dollars of the comparable period of the prior year.

The weighted average foreign exchange rates were $1.399 and $1.385 per US$1.00 for the three and nine months ended September 30, 2026, respectively and $1.378 and $1.400 per US$1.00 for the three and nine months ended September 30, 2025, respectively. On a constant currency basis, the Company’s net income for the three and nine months ended September 30, 2026 would have been lower by $10 million ($0.02 per diluted share) and higher by $16 million ($0.03 per diluted share), respectively.

The following table provides a reconciliation of the impact of constant currency and related percentage change at constant currency on the financial results, as reported for the three and nine months ended September 30, 2026:

	Three months ended September 30											Nine months ended September 30
In millions, except per share data		2026		Constant currency impact				2025		% Change at constant currency Fav (Unfav)			2026		Constant currency impact				2025		% Change at constant currency Fav (Unfav)
Revenues
Petroleum and chemicals	$	1,000		$	(9	)	$	854		16	%	$	2,869		$	16		$	2,577		12	%
Metals and minerals		561			(6	)		477		16	%		1,557			11			1,496		5	%
Forest products		495			(6	)		451		8	%		1,424			10			1,406		2	%
Coal		246			(2	)		237		3	%		708			2			725		(2	%)
Grain and fertilizers		923			(7	)		775		18	%		2,952			17			2,560		16	%
Intermodal		1,065			(4	)		980		8	%		3,114			7			2,928		7	%
Automotive		284			(3	)		217		29	%		776			4			677		15	%
Total freight revenues		4,574			(37	)		3,991		14	%		13,400			67			12,369		9	%
Other revenues		197			(2	)		174		12	%		503			1			471		7	%
Total revenues		4,771			(39	)		4,165		14	%		13,903			68			12,840		9	%
Operating expenses
Labor and fringe benefits		871			(5	)		815		(6	%)		2,674			11			2,597		(3	%)
Purchased services and material		628			(3	)		562		(11	%)		1,892			3			1,715		(10	%)
Fuel		662			(10	)		418		(56	%)		1,804			16			1,349		(35	%)
Depreciation and amortization		496			(4	)		500		2	%		1,466			5			1,482		1	%
Equipment rents		108			(1	)		103		(4	%)		326			3			326		(1	%)
Other		158			(1	)		161		2	%		563			3			517		(9	%)
Asset impairments		118			—			—		—	%		118			—			—		—	%
Total operating expenses		3,041			(24	)		2,559		(18	%)		8,843			41			7,986		(11	%)
Operating income		1,730			(15	)		1,606		7	%		5,060			27			4,854		5	%
Interest expense		(245	)		3			(227	)	(7	%)		(720	)		(5	)		(679	)	(7	%)
Other components of net periodic benefit income		133			—			125		6	%		399			—			376		6	%
Other income		3			—			3		—	%		83			—			44		89	%
Income before income taxes		1,621			(12	)		1,507		7	%		4,822			22			4,595		5	%
Income tax expense		(412	)		2			(368	)	(11	%)		(1,218	)		(6	)		(1,123	)	(9	%)
Net income	$	1,209		$	(10	)	$	1,139		5	%	$	3,604		$	16		$	3,472		4	%
Diluted earnings per share	$	2.00		$	(0.02	)	$	1.83		8	%	$	5.93		$	0.03		$	5.54		8	%
Adjusted net income (1)	$	1,307		$	(10	)	$	1,139		14	%	$	3,670		$	16		$	3,472		6	%
Adjusted diluted earnings per share (1)	$	2.16		$	(0.02	)	$	1.83		17	%	$	6.03		$	0.03		$	5.54		9	%

(1)

These non-GAAP measures do not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies. See the section of this MD&A entitled Adjusted performance measures for an explanation and reconciliation of these non-GAAP measures. Adjusted net income at constant currency and adjusted diluted EPS at constant currency allow results to be viewed without the impact of fluctuations in foreign currency exchange rates, thereby facilitating period-to-period comparisons in the analysis of trends in business performance. For the three months ended September 30, 2026, the Adjusted net income at constant currency was $1,297 million, calculated as adjusted net income of $1,307 million, adjusted for the impact of fluctuations in foreign currency exchange rates of $10 million. For the nine months ended September 30, 2026, the Adjusted net income at constant currency was $3,686 million, calculated as adjusted net income of $3,670 million, adjusted for the impact of fluctuations in foreign currency exchange rates of $16 million. For the three months ended September 30, 2026, the Adjusted diluted EPS at constant currency was $2.14, calculated as adjusted diluted EPS of $2.16, adjusted for the impact of fluctuations in foreign currency exchange rates of $0.02 per diluted share. For the nine months ended September 30, 2026, the Adjusted diluted EPS at constant currency was $6.06, calculated as adjusted diluted EPS of $6.03, adjusted for the impact of fluctuations in foreign currency exchange rates of $0.03 per diluted share.

Adjusted debt-to-adjusted EBITDA multiple

Management believes that the adjusted debt-to-adjusted EBITDA multiple is a useful credit measure because it reflects the Company’s ability to service its debt and other long-term obligations. The Company calculates the adjusted debt-to-adjusted EBITDA multiple as adjusted debt divided by the last twelve months of adjusted EBITDA. Adjusted debt is defined as the sum of Long-term debt and Current portion of long-term debt as reported on the Company’s Consolidated Balance Sheets as well as Operating lease liabilities, including current portion and pension plans in deficiency recognized on the Company’s Consolidated Balance Sheets due to the debt-like nature of their contractual and financial obligations. Adjusted EBITDA is calculated as Net income excluding Interest expense, Income tax expense, Depreciation and amortization, operating lease cost, Other components of net periodic benefit income, Other income (loss), and other significant items that are not reflective of CN’s underlying business operations and which could distort the analysis of trends in business performance. Adjusted debt and adjusted EBITDA are non-GAAP measures used to compute the adjusted debt-to-adjusted EBITDA multiple. These measures do not have any standardized meaning prescribed by GAAP and therefore, may not be comparable to similar measures presented by other companies.

The following table provides a reconciliation of debt and Net income in accordance with GAAP, reported as at and for the twelve months ended September 30, 2026 and 2025, to the adjusted measures presented herein, which have been used to calculate the non-GAAP adjusted debt-to-adjusted EBITDA multiple:

In millions, unless otherwise indicated	As at and for the twelve months ended September 30,		2026			2025
Debt (1)		$	22,812		$	21,120
Adjustments:
Operating lease liabilities, including current portion (2)			534			452
Pension plans in deficiency (3)			333			341
Adjusted debt		$	23,679		$	21,913
Net income		$	4,852		$	4,618
Interest expense			954			910
Income tax expense			1,639			1,485
Depreciation and amortization			1,922			1,971
Operating lease cost (4)			150			159
Other components of net periodic benefit income			(525	)		(489	)
Other income			(127	)		(42	)
Adjustments:
Workforce reduction program (5)			34			—
Advisory costs related to rail consolidation matters (6)			63			—
Asset impairments (7)			118			—
Adjusted EBITDA		$	9,080		$	8,612
Adjusted debt-to-adjusted EBITDA multiple (times)			2.61			2.54

(1)	Represents the aggregate of Current portion of long-term debt and Long-term debt as disclosed on the Consolidated Balance Sheets.
(2)	Represents the present value of operating lease payments.
(3)	Represents the total funded deficit of all defined benefit pension plans with a projected benefit obligation in excess of plan assets.
(4)	Represents the operating lease costs recorded in Purchased services and material and Equipment rents within the Consolidated Statements of Income.
(5)	Relates to employee termination benefits and severance costs related to a workforce reduction program, recorded in the fourth quarter of 2025 in Labor and fringe benefits within the Consolidated Statements of Income.
(6)	Represents advisory costs related to the analysis and advocacy for the STB review of the impacts to fair competition pertaining to the potential merger between Union Pacific and Norfolk Southern recorded in Purchased services and material within the Consolidated Statements of Income.
(7)	Represents an impairment related to the discontinued development of portions of certain components of its dispatching and back office information technology projects before completion recorded in Asset impairments within the Consolidated Statements of Income. See Note 6 – Properties to the Company’s unaudited Interim Consolidated Financial Statements for additional information.

The Extraordinary General Meeting (the “EGM”) in INQ Group AB (publ) (the ”Company”) was held today on 30 October 2026 and in particular the following resolutions were adopted.

The resolutions aim, among other things, to enable conversion of participations in Tranche 7 under the Company’s Amended and Restated Secured Convertible Agreement into ordinary shares.

Authorisation for the Board of Directors to resolve on issues

The EGM authorised the Board of Directors to resolve, until the next Annual General Meeting, with or without deviation from the shareholders’ preferential rights, on the issue of ordinary shares, warrants and/or convertibles. Disregarding any issues before the EGM under the authorisation resolved by the Annual General Meeting under item 14(e) (which shall be deducted), the authorisation comprises a maximum of 339,944,716 ordinary shares and replaces the authorisation to issue up to 390,000,000 ordinary shares by way of directed issue and/or rights issue resolved by the Annual General Meeting on 31 July 2026 (item 14(e)), to the extent not already exercised. The purpose is to increase the Company’s financial flexibility, broaden the shareholder base with strategic or long-term investors and enable conversion under the Company’s existing convertible agreements.

Amendment of the resolution on consolidation of shares (1:100)

Under the resolution of the Annual General Meeting on 31 July 2026, the consolidation of shares (1:100) was to be based on a share quota value of SEK 0.13 per share, resulting in a new share quota value of SEK 13 per share. As a result of the share issues, the reduction of the share capital and the bonus issue resolved on at the Annual General Meeting, and the share issues resolved on at today’s EGM, the quota value at the time of the consolidation will not correspond to these amounts. The EGM therefore resolved that the consolidation shall instead be carried out on the basis of the quota value applicable at the time of the consolidation, and that the Board of Directors shall determine that quota value and the quota value following the consolidation. The Board of Directors was also authorised to determine the record date and the order in which the consolidation and the registration of the share issues are carried out. The other terms remain unchanged.

Directed issues to subscribers in Tranche 7

The EGM resolved on two directed issues of a total of 45,642,164 ordinary shares to the subscribers in Tranche 7, including the Chairman of the Board of Directors and the Chief Executive Officer, with payment by way of set-off of their claims. The subscription price is SEK 0.16 per share, corresponding to the contractual conversion price, applying a fixed exchange rate of SEK/USD 9.05. The purpose is to convert debt into equity and strengthen the Company’s balance sheet.

Attachment

• Stämmokommuniké från extra bolagsstämma den 30 oktober 2026 i INQ Group AB (publ)